Javier Loricera1, Ricardo Blanco1, José L Hernández1, Santos Castañeda2, Alicia Humbría2, Norberto Ortego3, Beatriz Bravo4, Mercedes Freire5, Sheila Melchor6, Mauricio Mínguez7, Juan Salvatierra3, Carmen González-Vela1, Vanesa Calvo-Río1, Montserrat Santos-Gómez1, Trinitario Pina1, Miguel A González-Gay8. 1. Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain. 2. Department of Rheumatology, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain. 3. Department of Autoimmune Diseases, Hospital San Cecilio, Granada, Spain. 4. Unit of Paediatric Rheumatology, Hospital Virgen de las Nieves, Granada, Spain. 5. Department of Rheumatology, Complexo Hospitalario A Coruña (CHUAC), Spain. 6. Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain. 7. Department of Rheumatology, Hospital Universitario San Juan, Alicante, Spain. 8. Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain. miguelaggay@hotmail.com.
Abstract
OBJECTIVES: To assess the efficacy of tocilizumab (TCZ) in patients with Takayasu arteritis (TA). METHODS: Multicentre open-label retrospective study. RESULTS: Eight patients (all women) with a mean age of 34±16 years, median 36 years (range: 7-57) were assessed. The main clinical features at TCZ therapy onset were: constitutional symptoms (n=4), fever (n=3), headache (n=2), chest pain (n=1), abdominal pain (n=1), mesenteric ischaemia (n=1), myalgia involving the lower limbs (n=1), cerebral vascular insufficiency (n=1), malaise (n=1), upper limb claudication (n=1) and nodular scleritis (n=1). Besides corticosteroids and before TCZ treatment onset, 7 of 8 patients had also received several conventional immunosuppressive and/or biologic agents. Seven patients experienced marked clinical improvement in the first 3 months after the onset of TCZ therapy. After a median follow-up of 15.5 [interquartile range-IQR: 12-24] months, 7 patients were asymptomatic. The median C-reactive protein decreased from 3.09 [IQR: 0.5-12] to 0.15 [IQR: 0.1-0.5] mg/dL (p=0.018), and median erythrocyte sedimentation rate from 40 [IQ range: 28-72] to 3 [IQR: 2-5] mm/1st hour (p=0.012). The median dose of prednisone was also tapered from 42.5 [IQR: 25-50] to 2.5 [IQR: 0-7.5] mg/day (p=0.011). However, TCZ had to be discontinued in 1 patient because she developed a systemic lupus erythematosus, and in another patient due to inefficiency. TCZ dose was reduced in a patient because of mild thrombocytopenia. CONCLUSIONS: TCZ appears to be effective in the management of patients with TA, in particular in patients refractory to corticosteroids and/or conventional immunosuppressive drugs.
OBJECTIVES: To assess the efficacy of tocilizumab (TCZ) in patients with Takayasu arteritis (TA). METHODS: Multicentre open-label retrospective study. RESULTS: Eight patients (all women) with a mean age of 34±16 years, median 36 years (range: 7-57) were assessed. The main clinical features at TCZ therapy onset were: constitutional symptoms (n=4), fever (n=3), headache (n=2), chest pain (n=1), abdominal pain (n=1), mesenteric ischaemia (n=1), myalgia involving the lower limbs (n=1), cerebral vascular insufficiency (n=1), malaise (n=1), upper limb claudication (n=1) and nodular scleritis (n=1). Besides corticosteroids and before TCZ treatment onset, 7 of 8 patients had also received several conventional immunosuppressive and/or biologic agents. Seven patients experienced marked clinical improvement in the first 3 months after the onset of TCZ therapy. After a median follow-up of 15.5 [interquartile range-IQR: 12-24] months, 7 patients were asymptomatic. The median C-reactive protein decreased from 3.09 [IQR: 0.5-12] to 0.15 [IQR: 0.1-0.5] mg/dL (p=0.018), and median erythrocyte sedimentation rate from 40 [IQ range: 28-72] to 3 [IQR: 2-5] mm/1st hour (p=0.012). The median dose of prednisone was also tapered from 42.5 [IQR: 25-50] to 2.5 [IQR: 0-7.5] mg/day (p=0.011). However, TCZ had to be discontinued in 1 patient because she developed a systemic lupus erythematosus, and in another patient due to inefficiency. TCZ dose was reduced in a patient because of mild thrombocytopenia. CONCLUSIONS:TCZ appears to be effective in the management of patients with TA, in particular in patients refractory to corticosteroids and/or conventional immunosuppressive drugs.
Authors: Sophie I Mavrogeni; Petros P Sfikakis; Theodoros Dimitroulas; Loukia Koutsogeorgopoulou; Gikas Katsifis; George Markousis-Mavrogenis; Genovefa Kolovou; George D Kitas Journal: Rheumatol Int Date: 2018-03-07 Impact factor: 2.631
Authors: Carol A Langford; David Cuthbertson; Steven R Ytterberg; Nader Khalidi; Paul A Monach; Simon Carette; Philip Seo; Larry W Moreland; Michael Weisman; Curry L Koening; Antoine G Sreih; Robert Spiera; Carol A McAlear; Kenneth J Warrington; Christian Pagnoux; Kathleen McKinnon; Lindsy J Forbess; Gary S Hoffman; Renée Borchin; Jeffrey P Krischer; Peter A Merkel Journal: Arthritis Rheumatol Date: 2017-03-08 Impact factor: 10.995
Authors: Diana Prieto-Peña; Pilar Bernabeu; Paloma Vela; Javier Narváez; Jesús C Fernández-López; Mercedes Freire-González; Beatriz González-Álvarez; Roser Solans-Laqué; José L Callejas Rubio; Norberto Ortego; Carlos Fernández-Díaz; Esteban Rubio; Salvador García-Morillo; Mauricio Minguez; Cristina Fernández-Carballido; Eugenio de Miguel; Sheila Melchor; Eva Salgado; Beatriz Bravo; Susana Romero-Yuste; Juan Salvatierra; Cristina Hidalgo; Sara Manrique; Carlos Romero-Gómez; Patricia Moya; Noelia Álvarez-Rivas; Javier Mendizabal; Francisco Ortiz-Sanjuán; Iván Pérez de Pedro; José L Alonso-Valdivielso; Laura Perez-Sanchez; Rosa Roldán; Nagore Fernandez-Llanio; Ricardo Gómez de la Torre; Silvia Suarez; María Jesús Montesa Cabrera; Mónica Delgado Sánchez; Javier Loricera; Belén Atienza-Mateo; Santos Castañeda; Miguel A González-Gay; Ricardo Blanco Journal: Ther Adv Musculoskelet Dis Date: 2021-06-18 Impact factor: 5.346
Authors: Ana F Águeda; Sara Monti; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Bhaskar Dasgupta; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich Journal: RMD Open Date: 2019-09-23